Aprea Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	46.47	14.6	22.85	21.61	28.79	53.08
Cash & Short-Term Investments	46.47	14.6	22.85	21.61	28.79	53.08
Cash Growth	141.06%	-36.11%	5.75%	-24.94%	-45.76%	-40.38%
Other Current Assets	0.78	0.96	0.73	0.91	1.37	3.51
Total Current Assets	47.25	15.56	23.58	22.52	30.15	56.58
Net Property, Plant & Equipment	0.05	0.06	0.08	0.09	0	0.21
Other Long-Term Assets	0.31	0.31	0.32	0.04	-	0.03
Total Assets	47.61	15.93	23.98	22.65	30.16	56.82
Accounts Payable	2.94	0.71	1.35	1.67	0.84	1.77
Accrued Expenses	2.36	2.05	2.01	2.19	2.36	5.35
Current Portion of Leases	-	-	-	-	-	0.19
Unearned Revenue	-	-	-	0.53	-	-
Total Current Liabilities	5.3	2.76	3.36	4.39	3.2	7.32
Total Liabilities	5.3	2.76	3.36	4.39	3.2	7.32
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-in Capital	389.13	356.71	350.97	335.64	330.06	241
Accumulated Other Comprehensive Income	-10.63	-10.63	-10.63	-10.61	-10.62	-10.36
Retained Earnings	-336.93	-333.64	-321.04	-308.08	-293.8	-181.13
Total Common Shareholders' Equity	41.59	12.44	19.31	16.95	25.64	49.51
Minority Interest	0.73	0.73	1.31	1.31	1.31	-
Shareholders' Equity	42.32	13.17	20.62	18.26	26.95	49.51
Total Liabilities & Equity	47.61	15.93	23.98	22.65	30.16	56.82
Total Debt	-	0	0	0	0	0.19
Net Cash (Debt)	46.47	14.6	22.85	21.61	28.79	52.89
Net Cash Growth	141.06%	-36.11%	5.75%	-24.94%	-45.57%	-40.37%
Net Cash Per Share	5.34	2.23	4.15	5.97	17.37	49.69
Book Value	41.59	12.44	19.31	16.95	25.64	49.51
Book Value Per Share	4.78	1.90	3.50	4.69	15.48	46.51
Tangible Book Value	41.59	12.44	19.31	16.95	25.64	49.51
Tangible Book Value Per Share	4.78	1.90	3.50	4.69	15.48	46.51

SEC Filings: 10-K · 10-Q